NRSN

NeuroSense Therapeutics NasdaqCM:NRSN Stock Report

Last Price

US$2.74

Market Cap

US$32.0m

7D

64.5%

1Y

n/a

Updated

29 Jun, 2022

Data

Company Financials +
NRSN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NRSN Stock Overview

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases.

NeuroSense Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NeuroSense Therapeutics
Historical stock prices
Current Share PriceUS$2.74
52 Week HighUS$8.18
52 Week LowUS$1.23
Beta0
1 Month Change83.89%
3 Month Change-30.98%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-32.18%

Recent News & Updates

Mar 31

Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?

NRSN is a clinical-stage biotech developing therapeutics for neurodegenerative diseases, including ALS. The company's "PrimeC" drug candidate has shown promising efficacy results and is expected to start a Phase 2b. The stock looks interesting considering the opportunity and several expected catalysts through 2022.

Shareholder Returns

NRSNUS BiotechsUS Market
7D64.5%3.8%1.6%
1Yn/a-25.8%-20.8%

Return vs Industry: Insufficient data to determine how NRSN performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how NRSN performed against the US Market.

Price Volatility

Is NRSN's price volatile compared to industry and market?
NRSN volatility
NRSN Average Weekly Movement18.7%
Biotechs Industry Average Movement13.1%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: NRSN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: NRSN's weekly volatility has decreased from 62% to 19% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201711Alon Ben-Noonhttps://www.neurosense-tx.com

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company’s preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer’s disease.

NeuroSense Therapeutics Fundamentals Summary

How do NeuroSense Therapeutics's earnings and revenue compare to its market cap?
NRSN fundamental statistics
Market CapUS$31.99m
Earnings (TTM)-US$4.63m
Revenue (TTM)n/a

0.0x

P/S Ratio

-6.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NRSN income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$4.63m
Earnings-US$4.63m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.40
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NRSN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is NRSN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NRSN?

Other financial metrics that can be useful for relative valuation.

NRSN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-2.7x
PEG Ration/a

Price to Book Ratio vs Peers

How does NRSN's PB Ratio compare to its peers?

NRSN PB Ratio vs Peers
The above table shows the PB ratio for NRSN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average0.8x
MTCR Metacrine
0.5xn/aUS$21.2m
SLNO Soleno Therapeutics
0.9x66.0%US$23.6m
SBFM Sunshine Biopharma
1.4xn/aUS$18.0m
FBRX Forte Biosciences
0.5xn/aUS$19.2m
NRSN NeuroSense Therapeutics
2.6x-5.0%US$32.0m

Price-To-Book vs Peers: NRSN is expensive based on its Price-To-Book Ratio (2.6x) compared to the peer average (0.8x).


Price to Earnings Ratio vs Industry

How does NRSN's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: NRSN is expensive based on its Price-To-Book Ratio (2.6x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is NRSN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NRSN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NRSN's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of NRSN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NRSN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NRSN's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NRSN's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is NeuroSense Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-5.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NRSN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NRSN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NRSN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NRSN is forecast to have no revenue next year.

High Growth Revenue: NRSN is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NRSN's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has NeuroSense Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


0.2%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: NRSN is currently unprofitable.

Growing Profit Margin: NRSN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if NRSN's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare NRSN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NRSN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: NRSN has a negative Return on Equity (-38.26%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is NeuroSense Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NRSN's short term assets ($14.0M) exceed its short term liabilities ($1.2M).

Long Term Liabilities: NRSN's short term assets ($14.0M) exceed its long term liabilities ($1.0M).


Debt to Equity History and Analysis

Debt Level: NRSN is debt free.

Reducing Debt: NRSN has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NRSN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: NRSN has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 42.9% each year.


Discover healthy companies

Dividend

What is NeuroSense Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NRSN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NRSN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NRSN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NRSN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NRSN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Alon Ben-Noon (42 yo)

6.42yrs

Tenure

Mr. Alon Ben-Noon is the Co-Founder of NeuroSense Therapeutics Ltd. and serves as its Chief Executive Officer since 2016 and Director since February 2017. Mr. Ben-Noon served as Chair of Board of Directors...


Leadership Team

Experienced Management: NRSN's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: NRSN's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: NRSN only recently listed within the past 12 months.


Top Shareholders

Company Information

NeuroSense Therapeutics Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: NeuroSense Therapeutics Ltd.
  • Ticker: NRSN
  • Exchange: NasdaqCM
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$31.987m
  • Shares outstanding: 11.67m
  • Website: https://www.neurosense-tx.com

Number of Employees


Location

  • NeuroSense Therapeutics Ltd.
  • Building B
  • 11 HaMenofim Street
  • Herzliya
  • 4672562
  • Israel

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/29 00:00
End of Day Share Price2022/06/29 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.